{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'injection and compared between the two groups using identical', 'paper diaries. Serious adverse events and events of clinical', 'interest will be assessed through 42 days post-vaccination and', 'compared between the two groups.', 'Health-related quality of life will be assessed at baseline before', 'vaccination, at day 3 and day 9 post-vaccination. Perceptions', 'of the vaccination study experience and adverse event', 'monitoring experience will be assessed at days 9 and 29 post-', 'vaccination.', 'Vaccine strain-specific serum hemagglutination inhibition', 'antibody titers will be measured from blood samples collected', 'pre- and 29 days post-immunization for all participants and for', 'approximately 100 subjects at Duke on Day 181 (Year 1 only).', 'Vaccine reactogenicity, serious adverse events (SAEs) and', 'events of clinical interest, health related quality of life, and', 'vaccine strain-specific serum hemagglutination inhibition', 'antibody titers pre- and 29 days post-immunization will be', 'measured in a subset of 60 subjects in a repeat vaccination', 'sub-study (at Duke only). Subjects in the second year of the', 'repeat vaccination sub-study will be assigned to receive the', 'same vaccination that they received the first year.', 'Objectives:', 'Primary Objectives:', '1. To compare the proportions of moderate/severe', 'injection-site pain after allV3 and IIV3-HD in the full', 'study population', 'a.', 'Hypothesis: the proportion of subjects who', 'have moderate/severe injection site pain within', 'the first week post-vaccination will be non-', 'inferior for allV3 compared to IIV3-HD in the full', 'study population', '2. To compare serious adverse events and events of', 'clinical interest after allV3 and IIV3-HD in the full study', 'population and by age-group', '3. To compare the seroconversion rate for the H3N2', 'influenza A strain after allV3 and IIV3-HD in the full', 'study population', '6']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'a. Hypothesis: the seroconversion rate for the', 'H3N2 influenza A strain in the full study', 'population after allV3 will be non-inferior to IIV-', 'HD', 'Secondary Objectives', '1.', 'To compare the proportions of local and systemic', 'reactions (other than moderate/severe injection site', 'pain) after allV3 and IIV3-HD in the full study', 'population and by age-group (65-79 years and >80', 'years)', '2.', 'To describe and compare changes in health-related', 'quality of life after allV3 and IIV3-HD in the full study', 'population and by age-group', '3. To compare serum hemagglutination inhibition (HAI)', 'antibody titers after allV3 and IIV3-HD for each of the', 'three influenza vaccine strains contained in the', 'respective vaccine for that season in the full study', 'population and by age (except for seroconversion for', 'the H3N2 strain in the full study population)', 'Exploratory Objectives:', '1. To describe how the reactogenicity events affect', 'health-related quality of life after IIV3 and IIV3-HD in', 'the full study population and by age-group', '2. To describe and compare participant perceptions of the', 'vaccination experience', '3. To describe participant perceptions of methods of', 'adverse event monitoring in older adults receiving', 'influenza vaccines.', '4. To describe injection site pain immediately after', 'vaccination after allV3 and IIV3-HD', '5. To describe and compare the proportions of immediate', 'adverse events after allV3 and IIV3-HD and unsolicited', 'adverse events in the full study population and by age-', 'group (65-79 years and >80 years)', '6. To describe factors (e.g., statin use) associated with', 'reactogenicity to allV3 and IIV3-HD', '7. To describe the safety of allV3 and IIV3-HD after', 'repeat administration of the same product over 2', 'consecutive influenza seasons in a subset of subjects', '8. To describe the relationship between reactogenicity', 'and immunogenicity for allV3 and IIV3-HD', '9. To explore factors (e.g., statin use) associated with', 'immunogenicity for allV3 and IIV3-HD', '7']\n\n###\n\n", "completion": "END"}